Is CASBF or QYLD a better dividend investment in 2026?

CASBF currently yields 51.81% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: CASBF offers higher current income.

What is the dividend yield difference between CASBF and QYLD?

CASBF has a forward dividend yield of 51.81% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 39.89 percentage points.

Home › Compare › CASBF vs QYLD

CASBF vs QYLD: Dividend Comparison 2026

CASBF yields 51.81% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CASBF wins by $4.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CASBF

● Live price

51.81%

Share price

$3.86

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.0K

Annual income

$7.71

Full CASBF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — CASBF vs QYLD

📍 CASBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CASBF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CASBF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CASBF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF

Annual income on $10K today (after 15% tax)

$4,404.15/yr

After 10yr DRIP, annual income (after tax)

$6.55/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, QYLD beats the other by $4,803.86/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + QYLD for your $10,000?

CASBF: 50%QYLD: 50%

100% QYLD50/50100% CASBF

Portfolio after 10yr

$27.7K

Annual income

$2,833.51/yr

Blended yield

10.23%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys

QYLD buys

Politician	Chamber	Ticker	Type	Amount	Date
Tim Moore	🏢 House	$QYLD	▼ Sell	$15,001 - $50,000	2025-05-02
Tim Moore	🏢 House	$QYLD	▲ Buy	$15,001 - $50,000	2025-04-07
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2022-11-14
Dwight Evans	🏢 House	$QYLD	▼ Sell	$1,001 - $15,000	2020-10-29

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCASBFQYLD

Forward yield	51.81% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	0% ✓
Portfolio after 10y	$30.0K ✓	$25.4K
Annual income after 10y	$7.71	$5,659.31 ✓
Total dividends collected	$6.0K	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: CASBF vs QYLD ($10,000, DRIP)

Year	CASBF Portfolio	CASBF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$13,291	$2,590.67	$10,352	$1,192.36	+$2.9K → CASBF
2	$15,830	$1,608.96	$10,830	$1,347.57	+$5.0K → CASBF
3	$17,834	$895.50	$11,460	$1,539.07	+$6.4K → CASBF
4	$19,553	$471.42	$12,275	$1,777.84	+$7.3K → CASBF
5	$21,164	$241.53	$13,323	$2,078.95	+$7.8K → CASBF
6	$22,767	$122.16	$14,667	$2,463.34	+$8.1K → CASBF
7	$24,422	$61.41	$16,396	$2,960.57	+$8.0K → CASBF
8	$26,163	$30.78	$18,631	$3,612.97	+$7.5K → CASBF
9	$28,010	$15.41	$21,548	$4,482.15	+$6.5K → CASBF
10	$29,978	$7.71	$25,398	$5,659.31	+$4.6K → CASBF

CASBF vs QYLD: Complete Analysis 2026

CASBF — Stock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this CASBF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHD CASBF vs JEPI CASBF vs O CASBF vs KO CASBF vs MAIN CASBF vs XYLD CASBF vs JEPQ CASBF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.